FDA Grants Breakthrough Therapy for Prostate Cancer Imaging Drug

SYDNEY, Nov. 12, 2026 /CourierPR/ -- The United States Food and Drug Administration (FDA) has granted 64Cu-SAR-bisPSMA Breakthrough Therapy designation, a significant milestone for Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company focused on developing next-generation products to improve treatment outcomes for cancer patients. The designation is intended to expedite the development and review of drugs that may demonstrate substantial improvement over available therapies, particularly in the context of prostate cancer.

This Breakthrough Therapy designation is a testament to the innovative approach and robust data generated by Clarity Pharmaceuticals, which includes results from two pivotal Phase III trials with 64Cu-SAR-bisPSMA. These trials, known as AMPLIFY (NCT06970847) and CLARIFY (NCT06056830), are expected to provide the necessary evidence for the FDA to approve 64Cu-SAR-bisPSMA as a new diagnostic imaging agent for prostate cancer patients prior to undergoing definitive therapy (CLARIFY) and with biochemical recurrence (AMPLIFY).

The FDA Breakthrough Therapy designation was supported by a wealth of data, including results from the Phase II Co-PSMA trial and the Phase I/II COBRA trial, as well as real-world evidence. These trials collectively indicate that 64Cu-SAR-bisPSMA offers enhanced diagnostic performance compared to standard-of-care (SOC) PSMA PET in patients with biochemical recurrence (BCR) of prostate cancer.

Clarity Pharmaceuticals' lead product, 64Cu-SAR-bisPSMA, represents a significant advancement in the field of prostate cancer detection. The drug's unique combination of imaging and therapy capabilities, enabled by Clarity's proprietary SAR Technology, sets it apart from FDA-approved PSMA PET products currently on the market. The longer half-life of copper-64, compared to the half-lives of gallium-68 and fluorine-18 isotopes, allows for extended imaging timepoints of up to 30 hours post-injection, providing clinicians with more comprehensive and detailed imaging data.

The Breakthrough Therapy designation also underscores the unmet need for more accurate detection of recurrent prostate cancer lesions, particularly in patients with small volume disease. Clarity Pharmaceuticals' lead product has demonstrated superior diagnostic performance in head-to-head comparisons against SOC PSMA PET agents, with a detection rate of 78% for 64Cu-SAR-bisPSMA compared to 47% for 68Ga-PSMA-11 and 35% for 18F-DCFPyL, respectively.

The FDA's Breakthrough Therapy designation is a crucial step towards bringing 64Cu-SAR-bisPSMA to market, where it can potentially improve the detection of prostate cancer and facilitate more informed, individualized clinical management for patients. The substantial and growing market for PSMA PET imaging, projected to reach over US$3 billion by 2029, represents a significant opportunity for Clarity Pharmaceuticals, but the company's focus remains firmly on developing products that will improve the outcomes of patients with cancer.

Clarity Pharmaceuticals is committed to supporting high-quality research involving 64Cu-SAR-bisPSMA, such as the investigator-initiated trial (IIT) led by Prof Louise Emmett at St Vincent's Hospital in Sydney, which evaluated the diagnostic performance of 64Cu-SAR-bisPSMA against SOC 68Ga-PSMA-11 in prostate cancer patients with PSA levels of 0.2 to 0.75 ng/mL. The study's findings, published in the prestigious European Urology journal, have been recognized globally and have contributed to the Breakthrough Therapy designation.

As pivotal trials for 64Cu-SAR-bisPSMA continue to demonstrate their potential, Clarity Pharmaceuticals remains dedicated to advancing the field of targeted copper theranostics (TCTs) and improving the lives of patients with cancer. The company's focus on innovation, scientific rigor, and highest standards of clinical development continues to drive the development of 64Cu-SAR-bisPSMA, which has the potential to revolutionize the way prostate cancer is diagnosed and managed.